AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

715.358

-3.575-0.50%

Number of Gainers:18

Number of Losers:12

Number of Flat:15

PE:- -

High:721.437

Open:718.050

Low:714.938

Close:718.933

Volume:41.77M

Turnover:240.24M

Market Cap:108.38B

Float Cap:105.23B

Loading ...

Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says

MT Newswires Live

OncoSil Medical Receives Positive Preliminary Results From Investigator-Initiated Pancreatic Cancer Study; Shares Up 14%

MT Newswires Live

Imugene Says Drug Candidate Trial in Blood Cancer Patients Achieves 81% Overall Response Rate; Shares Rise 8%

MT Newswires Live

Proteomics International Secures ISO 15189 Certification For Australian Diagnostic Lab Operations, Shares Up 3%

MT Newswires Live

Imricor Medical Systems Advances US FDA Review Process With Completion of Human Factors Study

MT Newswires Live

Imricor Medical Systems Inc - Succesfully Completes Human Factors Study for All Devices in FDA Approval Pathway

THOMSON REUTERS

NewMarket to Acquire Mars TopCo

MT Newswires Live

Oncosil Medical Ltd - Trading Halt Requested Pending Pancosil Trial Results

THOMSON REUTERS

ASX Growth Stocks With High Insider Ownership

Simply Wall St.

Race Oncology Files Three New Patent Applications After Scientific Discoveries, Shares Jump 24%

MT Newswires Live

Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery

BRIEF-CSL Partners On New Coagulation Treatment

Orthocell Says Nerve Repair Product Introduced for Use in 'Nerve-Sparing' Robotic-Assisted Radical Prostatectomies, Shares Jump 9%

MT Newswires Live

CSL Partners with VarmX to Develop New Treatment for FXa Inhibitor Bleeding

MT Newswires Live

CSL Ltd - Varmx Will Receive Payments of up to US$388 Mln up to Launch of Vmx-C001, Plus Further Commercial Milestones Thereafter

THOMSON REUTERS

CSL Ltd - Entered Into an Agreement With Privately Held Dutch Biotech Company, Varmx BV

THOMSON REUTERS

CSL Ltd - Will Make an Upfront Payment to Varmx of US$117 Mln for an Exclusive Option to Acquire Company

THOMSON REUTERS

CSL Ltd - Agreement to Develop a New Treatment to Restore Blood Coagulation in Patients Taking a Fxa Inhibitor

THOMSON REUTERS

Mesoblast (ASX:MSB) Valuation in Focus After Ryoncil Launch and Pipeline Milestones Unveiled in New York

Simply Wall St.

Actinogen Medical Ltd. Achieves FDA Agreement for Streamlined Development of Alzheimer's Drug Xanamem

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":715.35785,"timestamp":1758174592057,"preClose":718.9331,"halted":0,"volume":41766631,"delay":0,"changeRate":-0.004973,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-3.575256,"latestTime":"09-18 15:49:52 AEST","open":718.05005,"high":721.43744,"low":714.9381,"amount":240242232,"amplitude":0.00904,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1758175200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1758153600000,1758175200000]],"turnoverRate":0.001495,"increases":20,"decrements":12,"flats":12,"marketCap":108378534424,"floatMarketCap":105234408874.3125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":721.43744,"amplitude":0.00904,"preClose":718.9331,"low":714.9381,"latestPrice":715.35785,"volume":41766631,"delay":0,"open":718.05005,"prevYearClose":936.801,"prevWeekClose":740.889,"prevMonthClose":762.058,"prevQuarterClose":795.022,"fiveDayClose":733.285,"twentyDayClose":798.289,"sixtyDayClose":793.519,"secType":"PLATE","market":"AU","turnoverRate":0.001495,"marketCap":108378534424,"floatMarketCap":105234408874.3125,"timestamp":1758174592057,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":18,"down":12,"flat":15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2568944090","title":"Botanix Pharmaceuticals' Topical Gel Launch Performs 'Exceptionally Well,' Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2568944090","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568944090?lang=en_us&edition=fundamental","pubTime":"2025-09-18 12:00","pubTimestamp":1758168019,"startTime":"0","endTime":"0","summary":"The launch of Botanix Pharmaceuticals'  topical gel, Sofdra, performed \"exceptionally well\" across multiple benchmarks, Euroz Hartleys said in a note on Wednesday.Sofdra outperformed all of its peers on launches on prescriptions, and net sales per representative, despite starting with only 27 representatives in the first two quarters.Adjusted for outcomes, Botanix operated 1.5 to 6 times more efficiently based on net sales generated per dollar of costs, compared with recent dermatology drug launches. The investment firm's analysis suggests that Sofdra has been the lowest-cost launch in the space.Weekly prescription volumes in early September are tracking over 50% above those in August. The prescriptions seem to be tracking broadly in line with its September-quarter forecasts, per the note.The investment firm maintained its buy recommendation and AU$0.44 per share price target on Botanix Pharmaceuticals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BOT.AU","BK7502","BK7508","BK7096"],"gpt_icon":0},{"id":"2568449281","title":"OncoSil Medical Receives Positive Preliminary Results From Investigator-Initiated Pancreatic Cancer Study; Shares Up 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568449281","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568449281?lang=en_us&edition=fundamental","pubTime":"2025-09-18 09:18","pubTimestamp":1758158297,"startTime":"0","endTime":"0","summary":"OncoSil Medical  received positive preliminary results from an investigator-initiated study, indicating that it is \"safe and feasible\" to deliver OncoSil by computerized tomography-guided percutaneous administration, according to a Thursday filing with the Australian bourse.OncoSil is a medical device that delivers a targeted dose of radiation directly into cancerous tissue in locally advanced pancreatic cancer.The procedure had a 90% technical success rate, with 10% of patients experiencing third-grade serious adverse device events, the filing said.The company anticipates securing additional regulatory approvals in the second half of fiscal 2026.Pancosil is a first-in-the-world study administering OncoSil through direct injection through the skin, according to the filing.OncoSil Medical shares rose 14% in morning trade Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","OSL.AU","BK7508"],"gpt_icon":0},{"id":"2568467974","title":"Imugene Says Drug Candidate Trial in Blood Cancer Patients Achieves 81% Overall Response Rate; Shares Rise 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568467974","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568467974?lang=en_us&edition=fundamental","pubTime":"2025-09-18 08:58","pubTimestamp":1758157126,"startTime":"0","endTime":"0","summary":"Imugene  said its Phase 1b clinical trial evaluating drug candidate azer-cel  in patients with blood cancer achieved an overall response rate  of 81%, up from an ORR of 79% in August, according to a Thursday filing with the Australian bourse.Thirteen out of sixteen patients showed a response to the treatment, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ORR.AU","BK7095","ORR","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2568446872","title":"Proteomics International Secures ISO 15189 Certification For Australian Diagnostic Lab Operations, Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568446872","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568446872?lang=en_us&edition=fundamental","pubTime":"2025-09-18 08:31","pubTimestamp":1758155460,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories  has been granted ISO 15189 certification for its Australian laboratory operations, a milestone in the commercialization and clinical use of its precision diagnostic tests, according to a Thursday Australian bourse filing.The ISO 15189 certification is the global standard specifically for medical laboratories, outlining the quality management and technical requirements necessary to ensure accurate and dependable test results, the filing added.The company's shares rose past 3% in recent Thursday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PIQ.AU","BK4121","ISO","XAO.AU","BK7508","XJO.AU","XKO.AU","BK7048"],"gpt_icon":0},{"id":"2568058445","title":"Imricor Medical Systems Advances US FDA Review Process With Completion of Human Factors Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2568058445","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568058445?lang=en_us&edition=fundamental","pubTime":"2025-09-18 08:27","pubTimestamp":1758155234,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems  said the human factors study covering all of its devices currently under review by the US Food and Drug Administration has been completed, according to a Thursday Australian bourse filing.The study is a critical step in the US FDA approval process, ensuring that each device can be used safely and effectively by clinicians in real-world settings, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMR.AU","BK7007","BK7503"],"gpt_icon":0},{"id":"2568444854","title":"Imricor Medical Systems Inc - Succesfully Completes Human Factors Study for All Devices in FDA Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2568444854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568444854?lang=en_us&edition=fundamental","pubTime":"2025-09-18 06:54","pubTimestamp":1758149644,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250917:nFWN3V410C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMR.AU","BK7007","BK7508","BK7503"],"gpt_icon":0},{"id":"2568495025","title":"NewMarket to Acquire Mars TopCo","url":"https://stock-news.laohu8.com/highlight/detail?id=2568495025","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568495025?lang=en_us&edition=fundamental","pubTime":"2025-09-17 20:24","pubTimestamp":1758111898,"startTime":"0","endTime":"0","summary":"NewMarket  said Wednesday it agreed to acquire Calca Solutions' parent company, Mars TopCo.Financial terms of the deal were not disclosed.Calca, currently a portfolio company of AE Industrial Partners, manufactures mission critical chemicals used for in-space propulsion by satellites, space probes and other space vehicles, NewMarket said.The company said it expects to use available cash and borrowings under its revolving credit facility to fund the acquisition, which is anticipated to close this year. Closing of the deal is subject to various conditions, including antitrust clearance, NewMarket said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NEU","NEU.AU","BK7508","BK4109"],"gpt_icon":0},{"id":"2568343143","title":"Oncosil Medical Ltd - Trading Halt Requested Pending Pancosil Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2568343143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568343143?lang=en_us&edition=fundamental","pubTime":"2025-09-17 06:41","pubTimestamp":1758062506,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nFWN3V30IO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","OSL.AU","BK7508"],"gpt_icon":0},{"id":"2568031455","title":"ASX Growth Stocks With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2568031455","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568031455?lang=en_us&edition=fundamental","pubTime":"2025-09-17 03:08","pubTimestamp":1758049690,"startTime":"0","endTime":"0","summary":"The Australian market showed signs of resilience as the index rebounded, taking cues from Wall Street's recent highs and anticipating potential economic shifts with the upcoming U.S. rate cut decision. Amid these fluctuating conditions, growth companies with high insider ownership can offer unique insights into their potential stability and commitment to long-term success, making them an intriguing focus for investors seeking solid opportunities in a dynamic environment.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-growth-stocks-with-high-insider-ownership-5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-dur/duratec-shares/news/asx-growth-stocks-with-high-insider-ownership-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EIQ.AU","ACR.AU","SKS.AU","WZR.AU","XAO.AU","IPX.AU","IMA.AU","BK7116","BK7158","BK7095","GTI.AU","3DP.AU","BK7043","BK7023","DUR.AU","FND.AU","BK7093","BK7508","BK7055","AV1.AU","XJO.AU","BK7016","XKO.AU","BK7096","NWF.AU"],"gpt_icon":0},{"id":"2567217502","title":"Race Oncology Files Three New Patent Applications After Scientific Discoveries, Shares Jump 24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567217502","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567217502?lang=en_us&edition=fundamental","pubTime":"2025-09-16 13:30","pubTimestamp":1758000658,"startTime":"0","endTime":"0","summary":"Race Oncology  filed a new composition of matter patent application as well as two additional patent applications covering the optimal manufacturing, formulation, and uses of (E,E)-bisantrene isomer after scientific discoveries into the nature of bisantrene, according to a Tuesday Australian bourse filing.The firm discovered that each isomer of bisantrene has differing biological properties and anticancer activity. The bisantrene isomers are generated during chemical synthesis or by exposure to visible light and heat. Only the (E,E)-bisantrene isomer has significant anticancer activity.The patent applications were filed on Sept. 12. They requested accelerated examination of the new applications to aid pharmaceutical partnering discussions.Its shares jumped 24% in recent trading on Tuesday, reaching the highest point in over two years.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2567173133","title":"Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery","url":"https://stock-news.laohu8.com/highlight/detail?id=2567173133","media":"prnewswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567173133?lang=en_us&edition=fundamental","pubTime":"2025-09-16 12:13","pubTimestamp":1757995980,"startTime":"0","endTime":"0","summary":"Potential to reduce the risk of erectile dysfunction and urinary incontinence. PERTH, Australia, Sept. 16, 2025 /PRNewswire/ --Regenerative medicine company Orthocell Limited  is pleased to announce its flagship nerve repair device, Remplir, has been introduced to Urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies . Remplir has been used in approximately 40 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery.Orthocell is collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia and will release the clinical data once available. The Company will also invest in further clinical studies to build evidence and assist medical education initiatives to drive further adoption of Remplir in this market.Orthocell is currently collaborating with urologists to collect and analyse retrospective outcome data from these nerve-sparing procedures using Remplir, wit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/globally-significant-opportunity-emerges-as-remplir-is-used-in-nerve-sparing-prostate-cancer-surgery-302557113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","XAO.AU","BK7508","XJO.AU","XKO.AU","BK7067"],"gpt_icon":0},{"id":"2567243121","title":"BRIEF-CSL Partners On New Coagulation Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2567243121","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567243121?lang=en_us&edition=fundamental","pubTime":"2025-09-16 09:19","pubTimestamp":1757985568,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Partners On New Coagulation TreatmentSept 16  - CSL Ltd CSL.AX:CSL PARTNERS ON NEW COAGULATION TREATMENTENTERED INTO AN AGREEMENT WITH PRIVATELY HELD DUTCH BIOTECH COMPANY, VARMX BVAGREEMENT TO DEVELOP A NEW TREATMENT TO RESTORE BLOOD COAGULATION IN PATIENTS TAKING A FXA INHIBITORWILL MAKE AN UPFRONT PAYMENT TO VARMX OF US$117 MILLION FOR AN EXCLUSIVE OPTION TO ACQUIRE COMPANYVARMX WILL RECEIVE PAYMENTS OF UP TO US$388 MILLION UP TO LAUNCH OF VMX-C001, PLUS FURTHER COMMERCIAL MILESTONES THEREAFTERFurther company coverage: CSL.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nFWN3V2176:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7067","BK7501","BK7511","BK7508"],"gpt_icon":0},{"id":"2567294431","title":"Orthocell Says Nerve Repair Product Introduced for Use in 'Nerve-Sparing' Robotic-Assisted Radical Prostatectomies, Shares Jump 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567294431","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567294431?lang=en_us&edition=fundamental","pubTime":"2025-09-16 08:43","pubTimestamp":1757983419,"startTime":"0","endTime":"0","summary":"Orthocell  said that its nerve repair product, Remplir, was introduced to urologists in Australia for use in \"nerve-sparing\" robotic-assisted radical prostatectomies, seeking to reduce post-surgical complications caused by peripheral nerve injury, according to a Tuesday Australian bourse filing.The firm is collecting clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia and will release the clinical data once it is available. Radical prostatectomy is associated with high rates of urinary incontinence and erectile dysfunction after treatment due to damage to the peripheral nerves surrounding the prostate.The firm will also invest in clinical studies to build evidence and assist medical education initiatives. It believes using Remplir in nerve-sparing robotic-assisted radical prostatectomies represents an opportunity to expand the product's total addressable market.Its shares jumped 9% in recent trading on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","XJO.AU","XKO.AU","BK7508","OCC.AU","XAO.AU"],"gpt_icon":0},{"id":"2567412560","title":"CSL Partners with VarmX to Develop New Treatment for FXa Inhibitor Bleeding","url":"https://stock-news.laohu8.com/highlight/detail?id=2567412560","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567412560?lang=en_us&edition=fundamental","pubTime":"2025-09-16 07:36","pubTimestamp":1757979393,"startTime":"0","endTime":"0","summary":"CSL  has partnered with VarmX to develop VMX-C001, a recombinant factor X protein to restore blood clotting in patients on Factor Xa inhibitors facing severe bleeding or requiring urgent surgery, according to a Tuesday Australian bourse filing.The FXa inhibitor is used by more than 20 million patients globally for chronic anticoagulation therapy, with around 3% experiencing severe bleeding or requiring urgent surgery, the filing said.The company will finance VarmX's global phase 3 trial and provide support for late-stage development, manufacturing, and pre-launch activities, per the filing.The company will make an upfront payment of $117 million to VarmX for an exclusive option to acquire the company following phase 3 results, with potential additional payments of up to $388 million plus commercial milestones.The treatment is slated for a commercial launch in 2029, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1169590202.USD","LU0728928796.USD","BK7511","LU1169589451.USD","CSL.AU","BK4086","BK7508","CSL","SGXZ23171101.USD","BK7501","BK7067","SG9999004303.SGD"],"gpt_icon":0},{"id":"2567908128","title":"CSL Ltd - Varmx Will Receive Payments of up to US$388 Mln up to Launch of Vmx-C001, Plus Further Commercial Milestones Thereafter","url":"https://stock-news.laohu8.com/highlight/detail?id=2567908128","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567908128?lang=en_us&edition=fundamental","pubTime":"2025-09-16 06:01","pubTimestamp":1757973714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nFWN3V2176:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"gpt_icon":0},{"id":"2567289091","title":"CSL Ltd - Entered Into an Agreement With Privately Held Dutch Biotech Company, Varmx BV","url":"https://stock-news.laohu8.com/highlight/detail?id=2567289091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567289091?lang=en_us&edition=fundamental","pubTime":"2025-09-16 06:01","pubTimestamp":1757973714,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nFWN3V2176:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7501","BK7508","BK7067","BK7511"],"gpt_icon":0},{"id":"2567128906","title":"CSL Ltd - Will Make an Upfront Payment to Varmx of US$117 Mln for an Exclusive Option to Acquire Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2567128906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567128906?lang=en_us&edition=fundamental","pubTime":"2025-09-16 06:01","pubTimestamp":1757973714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nFWN3V2176:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","CSL.AU","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2567128905","title":"CSL Ltd - Agreement to Develop a New Treatment to Restore Blood Coagulation in Patients Taking a Fxa Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2567128905","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567128905?lang=en_us&edition=fundamental","pubTime":"2025-09-16 06:01","pubTimestamp":1757973714,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nFWN3V2176:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7511","BK7501","BK7067","BK7508"],"gpt_icon":0},{"id":"2567514592","title":"Mesoblast (ASX:MSB) Valuation in Focus After Ryoncil Launch and Pipeline Milestones Unveiled in New York","url":"https://stock-news.laohu8.com/highlight/detail?id=2567514592","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567514592?lang=en_us&edition=fundamental","pubTime":"2025-09-15 21:56","pubTimestamp":1757944563,"startTime":"0","endTime":"0","summary":"If you are tracking Mesoblast (ASX:MSB), the company’s latest updates at major healthcare conferences in New York are tough to ignore. Mesoblast grabbed attention with news of a strong first quarter launch for Ryoncil, its FDA-approved therapy for pediatric steroid-refractory acute graft versus host disease (SR-aGvHD). In addition to highlighting early sales and new treatment sites coming online, management revealed plans to expand Ryoncil into additional indications, including adult SR-aGvHD...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-after-ryoncil-launch-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-after-ryoncil-launch-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK7067","MESO","MSB.AU","MSB","BK7501","BK4006","BK7508"],"gpt_icon":0},{"id":"2567111222","title":"Actinogen Medical Ltd. Achieves FDA Agreement for Streamlined Development of Alzheimer's Drug Xanamem","url":"https://stock-news.laohu8.com/highlight/detail?id=2567111222","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567111222?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:30","pubTimestamp":1757939429,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd. has announced a significant milestone in its ongoing efforts to gain regulatory approval for Xanamem, a treatment for Alzheimer's disease. Following a Type C meeting with the US Food & Drug Administration , the company has reached a common understanding with the agency on the pathway to marketing approval. This includes agreement on regulatory starting materials, the design of an additional pivotal clinical trial, and the limited number of ancillary clinical pharmacology trials and nonclinical studies required. The FDA's approval of the planned program allows Actinogen to proceed with confidence, aiming for a future US marketing approval of Xanamem. The ongoing XanaMIA pivotal phase 2/3 trial is on track, with interim analysis expected in January 2026 and final results later that year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL52kTd6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","ACW.AU","LU2095319765.USD","IE00BKPKM429.USD","LU2210149790.SGD","BK4112","BK7508","NDAQ","BK4585","BK7067","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":75,"code":"91000000","status":"200"}]}}